Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02141542
Title Phase I Clinical Trial of Tremelimumab Plus MEDI3617 in Patients With Unresectable Stage III or Stage IV Melanoma
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors F. Stephen Hodi, MD
Indications

melanoma

Therapies

Tremelimumab

MEDI3617

Age Groups: adult
Covered Countries USA


No variant requirements are available.